Link: https://links.sgx.com/1.0.0/corporate-announcements/9XGPMI707ZBGO0KQ/047f340c0a87c3e4e1ac2e202912499ba2b5a369335c0edfcdfa8f2dfcde1d36

Summary:

• Group revenue: S$7.4 million, down 19.8% year-on-year (mainly due to a slowdown in medical aesthetics treatments and manufacturing).

• Gross profit: Up 29% to S$3.5 million; gross margin improved to 47.4% (vs 29.5%), helped by strict cost controls and higher-margin skincare business.

• Net loss: S$659,000 (down 38% from S$1.06 million loss last year); net loss attributable to equity holders is only S$70,000.

• Cash position: S$4.96 million at end-September, working capital positive at S$600,000.

• Total assets: S$22.9 million; net asset value per share: 4.39 cents.

• AMS (Accrelist Medical Aesthetics) segment: Clinic network in Singapore and Malaysia holds steady revenue (S$7.1 million); margin and profitability improved due to cost discipline.

• Other segments: Skincare ODM sales rising, mechanical manufacturing subdued after Malaysia unit sale.

• No interim dividend declared—Board intends to conserve cash for business growth and investment opportunities.

• Expansion: New clinics planned in China, more retail skin product launches, increased investment in associated company Mclean Technologies Berhad (now 27% stake).

• Outlook: Medical aesthetics market remains resilient but competitive; management cautious on cost, focused on regional clinic network growth and new product lines to drive future profits.